Abstract
There was a major interest in the last years in the design of anticancer agents containing the 1,5-diaryl-3-oxo- 1,4-pentadienyl system. The modification of this pharmacophore by the introduction of an additional Michael acceptor represents a strategy to obtain novel potential antiproliferative agents. In a continuing study of hybrid compounds containing the α-bromoacryloyl moiety as potential anticancer drugs, we synthesized two novel series of hybrids 3a-i and 4a-i, in which this moiety was linked to the 1,5-diaryl-1,4-pentadien-3-one system. Many of the conjugates prepared (3b, 3c and 3g) demonstrated pronounced antiproliferative activity against five cancer cell lines, being more active than the reference compound Melphalan. Compounds 3e and 4b were also examined for their effects on the cell cycle progression of K562 cells. The detection of a sub-G1 peak upon incubation with these compounds suggested that 3e and 4b also exert their growth inhibiting effects by induction of apoptosis.
Keywords: bromoacryloyl moiety, diarylidene ketone, Inhibition of tumor cell growth, Antiproliferative agents, antiproliferative activities, lethal effects, malignant cells, -unsaturated ketones, pharmacophores, Michael acceptors, bromoacrylamido derivative, pyrroloiminoquinone, cytotoxic alkaloids
Letters in Drug Design & Discovery
Title: Design, Synthesis and Biological Evaluation of Hybrid Molecules Containing Conjugated Styryl Ketone and α-Bromoacryloyl Moieties
Volume: 9 Issue: 2
Author(s): Romeo Romagnoli, Pier Giovanni Baraldi, Olga Cruz-Lopez, Maria Kimatrai Salvador, Delia Preti, Mojgan Aghazadeh Tabrizi, Jan Balzarini, Alessandro Canella, Enrica Fabbri and Roberto Gambari
Affiliation:
Keywords: bromoacryloyl moiety, diarylidene ketone, Inhibition of tumor cell growth, Antiproliferative agents, antiproliferative activities, lethal effects, malignant cells, -unsaturated ketones, pharmacophores, Michael acceptors, bromoacrylamido derivative, pyrroloiminoquinone, cytotoxic alkaloids
Abstract: There was a major interest in the last years in the design of anticancer agents containing the 1,5-diaryl-3-oxo- 1,4-pentadienyl system. The modification of this pharmacophore by the introduction of an additional Michael acceptor represents a strategy to obtain novel potential antiproliferative agents. In a continuing study of hybrid compounds containing the α-bromoacryloyl moiety as potential anticancer drugs, we synthesized two novel series of hybrids 3a-i and 4a-i, in which this moiety was linked to the 1,5-diaryl-1,4-pentadien-3-one system. Many of the conjugates prepared (3b, 3c and 3g) demonstrated pronounced antiproliferative activity against five cancer cell lines, being more active than the reference compound Melphalan. Compounds 3e and 4b were also examined for their effects on the cell cycle progression of K562 cells. The detection of a sub-G1 peak upon incubation with these compounds suggested that 3e and 4b also exert their growth inhibiting effects by induction of apoptosis.
Export Options
About this article
Cite this article as:
Romagnoli Romeo, Giovanni Baraldi Pier, Cruz-Lopez Olga, Kimatrai Salvador Maria, Preti Delia, Aghazadeh Tabrizi Mojgan, Balzarini Jan, Canella Alessandro, Fabbri Enrica and Gambari Roberto, Design, Synthesis and Biological Evaluation of Hybrid Molecules Containing Conjugated Styryl Ketone and α-Bromoacryloyl Moieties, Letters in Drug Design & Discovery 2012; 9 (2) . https://dx.doi.org/10.2174/157018012799079842
DOI https://dx.doi.org/10.2174/157018012799079842 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Computational Polypharmacology with Text Mining and Ontologies
Current Pharmaceutical Biotechnology Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease
Current Drug Targets Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers A Natural Membrane Vesicle Exosome-based Sinomenine Delivery Platform for Hepatic Carcinoma Therapy
Current Topics in Medicinal Chemistry RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews New Insight in LPS Antagonist
Mini-Reviews in Medicinal Chemistry Changes in Gene Expression in the Rat Hippocampus Following Exposure to 56Fe Particles and Protection by Berry Diets
Central Nervous System Agents in Medicinal Chemistry ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Oncogenomics
Current Drug Metabolism Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Current Medicinal Chemistry